Rapid loss of vertebral mineral density after renal transplantation
- PMID: 1857390
- DOI: 10.1056/NEJM199108223250804
Rapid loss of vertebral mineral density after renal transplantation
Abstract
Background: Osteopenia is a major complication of renal transplantation. Immunosuppressive regimens including cyclosporine, which permit the use of lower doses of glucocorticoids, may reduce glucocorticoid-induced osteopenia.
Methods: We prospectively studied the magnitude, distribution, and mechanism of bone loss in 20 adults who received renal allografts from living related donors, who had good renal function, and who were treated with azathioprine, cyclosporine, and low doses of prednisone. We measured serum biochemical markers of bone metabolism, determined the bone mineral density of the second, third, and fourth lumbar vertebrae and the shaft of the radius, and analyzed the histomorphometric features of iliac bone at the time of transplantation and six months later. Measurements of vertebral mineral density were repeated 18 months after transplantation in 17 of the patients.
Results: After transplantation, the mean serum concentrations of parathyroid hormone, phosphorus, and alkaline phosphatase decreased and the serum calcitriol concentration increased. The mean (+/- SD) bone mineral density of the vertebrae had decreased 6.8 +/- 5.6 percent 6 months after transplantation (P less than 0.05) and 8.8 +/- 7.0 percent 18 months after transplantation. In contrast, the bone mineral density of the radius had increased six months after transplantation (P less than 0.05). The histomorphometric studies showed that the rate of bone formation decreased from 50.5 +/- 44.8 to 23.1 +/- 13.8 microns3 per square micrometer per year (P less than 0.05), and the formation period lengthened from 70 +/- 42 to 146 +/- 144 days (P less than 0.05). Consequently, the amount of bone replaced during a remodeling cycle diminished.
Conclusions: Osteopenia associated with renal transplantation remains a problem in the cyclosporine era. The loss of vertebral bone in our subjects was due to an imbalance in bone remodeling consistent with a toxic effect of glucocorticoids.
Similar articles
-
Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.Kidney Int. 2000 Oct;58(4):1788-96. doi: 10.1046/j.1523-1755.2000.00341.x. Kidney Int. 2000. PMID: 11012914 Clinical Trial.
-
Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study.Transplantation. 2006 Mar 27;81(6):826-31. doi: 10.1097/01.tp.0000203557.36884.e3. Transplantation. 2006. PMID: 16570003
-
Magnesium deficiency and bone loss after cardiac transplantation.J Bone Miner Res. 1999 Feb;14(2):295-303. doi: 10.1359/jbmr.1999.14.2.295. J Bone Miner Res. 1999. PMID: 9933485
-
[Long-term stability of bone mineral density in patients with renal transplant treated with cyclosporine and low doses of corticoids. Protective role of cyclosporine?].Presse Med. 1998 Apr 18;27(15):705-12. Presse Med. 1998. PMID: 9767908 Review. French.
-
Bone disease after kidney transplantation.Semin Nephrol. 2004 Jan;24(1):82-90. doi: 10.1053/j.semnephrol.2003.08.012. Semin Nephrol. 2004. PMID: 14730514 Review.
Cited by
-
The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes.Endocrine. 2015 Dec;50(3):568-74. doi: 10.1007/s12020-015-0632-8. Epub 2015 May 22. Endocrine. 2015. PMID: 25999028 Review.
-
Natural History of Bone Disease following Kidney Transplantation.J Am Soc Nephrol. 2022 Mar;33(3):638-652. doi: 10.1681/ASN.2021081081. Epub 2022 Jan 19. J Am Soc Nephrol. 2022. PMID: 35046132 Free PMC article.
-
Minimization of steroids in kidney transplantation.Transpl Int. 2009 Jan;22(1):38-48. doi: 10.1111/j.1432-2277.2008.00728.x. Epub 2008 Jul 24. Transpl Int. 2009. PMID: 18662366 Free PMC article. Review.
-
Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study.Transplant Proc. 1995 Feb;27(1):207-9. Transplant Proc. 1995. PMID: 7878974 Free PMC article. Clinical Trial. No abstract available.
-
Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study.PLoS One. 2012;7(11):e48481. doi: 10.1371/journal.pone.0048481. Epub 2012 Nov 20. PLoS One. 2012. PMID: 23185261 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical